Tesamorelin is a growth hormone releasing hormone analog that has been shown to increase IGF-1 levels in men by an average of 181 micrograms/liter. It binds and stimulates human GHRH receptors with similar potency as endogenous GHRH. It has a host of other benefits including nootropic effects and reducing triglycerides. Tesamorelin research has subsequently been shown to decrease carotid intima media thickness (cIMT), visceral adipose tissue (VAT), and C-reactive proteins (CRP) in a recent study. It has not been shown to significantly affect other pituitary hormones and their respective mechanisms in the body. Additionally, studies have shown it to improve cognitive function for healthy older adults and also for people with mild cognitive impairment who are at an increased risk of progressing to Alzheimer’s disease.

Ipamorelin is a selective GH-Secretagogue and ghrelin receptor agonist. The potency of ghrelin stimulation can be compared to GHRP6 with less appetite stimulation properties. However, unlike other GH-Secretagogues this pentapeptide doesn’t release the same volumes of cortisol, acetylcholine, prolactin and aldosterone. It is for this reason Ipamorelin has been considered the first selective GH-Secretagogue.

By combining both ipamorelin and tesamorelin, it may be possible to produce enhanced effects because each peptide stimulates the growth hormone axis via two different mechanisms. Together, they both work synergistically to stimulate the pituitary gland to produce and secrete your own natural growth hormone at more youthful levels. Research has shown that the net effect of combining both of these peptides results in better deep sleep, reduced triglycerides, VAT, and cIMT, improved cognition, and overall better metabolic function.

Ipamorelin and Tesamorelin exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Ipamorelin and Tesamorelin are for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy Ipamorelin and Tesamorelin if you are a licensed researcher.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

David E. Beck, MD, co-author of “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients” specializes in colon and rectal surgery.

David E. Beck, MD is being referenced as one of the leading scientists involved in the research and development of Ipamorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. David E. Beck, MD is listed in [4] under the referenced citations.

1. Adrian, S., et al. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging, 8(3):154-159. DOI: 10.14283/jfa.2018.45
2. Clemmons, D. R., Miller, S., & Mamputu, J. (2017). Safety and Metabolic Effects of Tesamorelin, A Growth Hormone-releasing Factor Analogue, in Patients with Type 2 Diabetes: A Randomized, Placebo-controlled Trial. PLoS One, 12(6): e0179538. DOI: 10.1371/journal.pone.0179538
3. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343.
4. Beck, David E., et al. “Prospective, Randomized, Controlled, Proof-of-Concept Study of the Ghrelin Mimetic Ipamorelin for the Management of Postoperative Ileus in Bowel Resection Patients.” International Journal of Colorectal Disease, vol. 29, no. 12, 21 Oct. 2014, pp. 1527–1534, 10.1007/s00384-014-2030-8.
5. Michael Ankersen, Nils L. Johansen, Kjeld Madsen, Birgit S. Hansen, Kirsten Raun, Karin Kramer Nielsen, Henning Thøgersen, Thomas K. Hansen, Bernd Peschke, Jesper Lau, Behrend F. Lundt, and Peter H. Andersen. A New Series of Highly Potent Growth Hormone-Releasing Peptides Derived from Ipamorelin. Journal of Medicinal Chemistry 1998 41 (19), 3699-3704. DOI: 10.1021/jm9801962
6. Raun, Kirsten & Hansen, B & Johansen, N & Thøgersen, Henning & Madsen, K & Ankersen, Michael & Hongaard Andersen, Peter. (1998). Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology / European Federation of Endocrine Societies. 139. 552-61. 10.1530/eje.0.1390552.
7. Fourman, L. T., et al. (2017). Visceral Fat Reduction with Tesamorelin is Associated with Improved Liver Enzymes in HIV. AIDS, 31(16):2253–2259. DOI: 10.1097/QAD.0000000000001614

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.